Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

August 19, 2021

Study Completion Date

February 26, 2024

Conditions
Melanoma
Interventions
DRUG

Talimogene laherparepvec

Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.

DRUG

Pembrolizumab

Intravenous (IV) infusion.

Trial Locations (46)

2060

Melanoma Institute Australia, North Sydney

3000

Peter MacCallum Cancer Centre, Melbourne

3004

The Alfred Hospital, Melbourne

4215

Tasman Oncology Research, Southport

5011

The Queen Elizabeth Hospital, Woodville South

11527

General Hospital of Athens Laiko, Athens

12208

New York Oncology Hematology, PC, Albany

19713

Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark

20014

Onkologikoa, Donostia / San Sebastian

20141

IRCCS Istituto Europeo di Oncologia, Milan

24127

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo

28046

Hospital Universitario La Paz, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

29010

Hospital Clinico Universitario Virgen de la Victoria, Málaga

30625

Medizinische Hochschule Hannover, Hanover

32806

University of Florida Health Cancer Center at Orlando Health, Orlando

33075

Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint André, Bordeaux

38043

Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon, Grenoble

40202

University of Louisville James Graham Brown Cancer Center, Louisville

44093

Centre Hospitalier Universitaire de Nantes, Hôpital Hôtel Dieu, Nantes

44195

Cleveland Clinic, Cleveland

45500

University Hospital of Ioannina, Ioannina

47014

"IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori", Meldola FC

55432

Allina Health Systems dba Virginia Piper Cancer Institute, Fridley

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

72076

Universitätsklinikum Tübingen, Tübingen

75010

Hopital Saint Louis, Paris

75246

Baylor Scott and White Research Institute, Dallas

77380

United States Oncology Regulatory Affairs Corporate Office, The Woodlands

78731

Texas Oncology Austin Central, Austin

93053

Universitätsklinikum Regensburg, Regensburg

93105

Sansum Clinic, Santa Barbara

94805

Gustave Roussy, Villejuif

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H3T 1E2

Jewish General Hospital, Montreal

G1R 2J6

CHU de Quebec-Universite Laval, Québec

01307

Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden

546 22

Bioclinic of Thessaloniki, Thessaloniki

1066 CX

Nederlands Kanker Instituut, Antoni van Leeuwenhoekziekenhuis, Amsterdam

3015 GD

Erasmus Medisch Centrum, Rotterdam

80-214

Uniwersyteckie Centrum Kliniczne Centrum Medycyny Nieinwazyjnej, Gdansk

60-780

Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Pozn, Poznan

02-781

"Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie †Panstwowy Instytut Badawczy", Warsaw

08035

Hospital Universitari Vall d Hebron, Barcelona

SE1 9RT

Guys Hospital, London

SW3 6JJ

Royal Marsden Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Amgen

INDUSTRY